Skip to main content
. 2014 Feb 3;2014:813067. doi: 10.1155/2014/813067

Figure 1.

Figure 1

Clinical impact of MYB in two cohorts of infiltrating ductal breast carcinomas. ANOVA test results of MYB (5586) mRNA levels in eight clinical indices, progesterone receptor (PR), HER-2/neu (HER), lymphovascular invasion (LVI), lymph nodal category (lymph node metastasis status (LYM) and number of lymph node metastasis (LNM)), age, tumor size (size), grade (nuclear pleomorphism, mitotic count, and tubule formation), and cancer stage in 91A cohort and 181A cohort, respectively ((a) and (b)). Lower panel, box plot analysis of MYB (5586) mRNA levels in four subtypes (i.e., Groups IE, IIE, triple negatives (TN), and ERBB2+) (c) and in two types (i.e. group IE (IE) and non-group IE(non-IE)) (d). The red dot line within box stands for the mean value for each subgroup in the plot. The black line within box stands for the median value for each subgroup in the plot. The survival analysis (Kaplan-Meier survival analysis) on a breast tumor group with high MYB mRNA levels versus the group with low MYB mRNA levels in 181A cohort (e). The Agilent feature number for MYB is 5586.